|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
immune system modulation
|
|
gptkbp:advocates_for
|
obtained
|
|
gptkbp:analysis
|
statistical analysis
|
|
gptkbp:analyzes
|
gptkb:Dr._John_Doe
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:2021
gptkb:United_States
gptkb:Native_American_tribe
NC T12345678
|
|
gptkbp:collaborations
|
gptkb:healthcare_organization
academic institutions
biotech companies
clinical research organizations
|
|
gptkbp:committee
|
established
|
|
gptkbp:contraindication
|
granted
|
|
gptkbp:developed_by
|
Cynk Technologies
|
|
gptkbp:dosage_form
|
gptkb:software_framework
|
|
gptkbp:duration
|
6 months
|
|
gptkbp:effective_date
|
gptkb:2022
|
|
gptkbp:events
|
1 year
|
|
gptkbp:field_of_study
|
oncology
|
|
gptkbp:frequency
|
weekly
|
|
gptkbp:future_plans
|
biomarker discovery
combination therapy
patient quality of life
long-term effects
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CYNK-001
|
|
gptkbp:indication
|
solid tumors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_studied_in
|
completed
open-label
|
|
gptkbp:is_tested_for
|
Phase 1
PD-L1 expression
immune cell infiltration
tumor mutational burden
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:participants
|
safety
efficacy
|
|
gptkbp:population
|
advanced cancer patients
|
|
gptkbp:publishes
|
clinical trial results
|
|
gptkbp:receives_funding_from
|
private investment
government grant
philanthropic donation
|
|
gptkbp:regulatory_compliance
|
investigational new drug
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
ongoing
fever
|
|
gptkbp:sponsor
|
Cynk Technologies
|
|
gptkbp:status
|
gptkb:legal_case
|
|
gptkbp:student_enrollment
|
adult patients
measurable disease
no prior treatment
solid tumor diagnosis
|
|
gptkbp:targets
|
gptkb:healthcare_organization
|
|
gptkbp:type
|
gptkb:vaccine
|
|
gptkbp:year
|
gptkb:2023
|
|
gptkbp:bfsParent
|
gptkb:Celularity_Inc.
|
|
gptkbp:bfsLayer
|
6
|